Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P55795
UPID:
HNRH2_HUMAN
Alternative names:
FTP-3; Heterogeneous nuclear ribonucleoprotein H'
Alternative UPACC:
P55795; A1L400; Q9HHA7
Background:
Heterogeneous nuclear ribonucleoprotein H2 (hnRNP H2), also known as FTP-3, plays a crucial role in the processing of pre-mRNAs into functional mRNAs, a fundamental step in gene expression. It binds specifically to poly(RG) sequences, indicating its involvement in the regulation of RNA metabolism.
Therapeutic significance:
The protein is linked to Intellectual developmental disorder, X-linked, syndromic, Bain type, characterized by developmental delay, intellectual disability, and seizures, among other symptoms. Targeting hnRNP H2 could offer new avenues for therapeutic interventions in treating this disorder.